Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy.

Victor E. Marquez; James A. Kelley; Riad Agbaria; Tisipi Ben-Kasus; Jonathan C. Cheng; Christine B. Yoo; Peter A. Jones

doi:10.1196/annals.1359.037

Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy.

Victor E. Marquez, James A. Kelley, Riad Agbaria, Tisipi Ben-Kasus, Jonathan C. Cheng, Christine B. Yoo, Peter A. Jones

Research output: Contribution to journal › Review article › peer-review

83 Scopus citations

Abstract

1-(Beta-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine) corresponds structurally to cytidine minus the exocyclic 4-amino group. The increased electrophilic character of its simple aglycon endows the molecule with unique biologic properties as a potent inhibitor of both cytidine deaminase and DNA cytosine methyltransferase. The latter activity makes zebularine a promising antitumor agent that is hydrolytically stable, preferentially targets cancer cells, and shows activity both in vitro and in experimental animals, even after oral administration.

Original language	English
Pages (from-to)	246-254
Number of pages	9
Journal	Annals of the New York Academy of Sciences
Volume	1058
DOIs	https://doi.org/10.1196/annals.1359.037
State	Published - 1 Jan 2005
Externally published	Yes

ASJC Scopus subject areas

General Neuroscience
General Biochemistry, Genetics and Molecular Biology
History and Philosophy of Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1196/annals.1359.037

Cite this

@article{00cfa87f6b0340e1ab39acb3aca1c7b0,

title = "Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy.",

abstract = "1-(Beta-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine) corresponds structurally to cytidine minus the exocyclic 4-amino group. The increased electrophilic character of its simple aglycon endows the molecule with unique biologic properties as a potent inhibitor of both cytidine deaminase and DNA cytosine methyltransferase. The latter activity makes zebularine a promising antitumor agent that is hydrolytically stable, preferentially targets cancer cells, and shows activity both in vitro and in experimental animals, even after oral administration.",

author = "Marquez, \{Victor E.\} and Kelley, \{James A.\} and Riad Agbaria and Tisipi Ben-Kasus and Cheng, \{Jonathan C.\} and Yoo, \{Christine B.\} and Jones, \{Peter A.\}",

year = "2005",

month = jan,

day = "1",

doi = "10.1196/annals.1359.037",

language = "English",

volume = "1058",

pages = "246--254",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Zebularine

T2 - a unique molecule for an epigenetically based strategy in cancer chemotherapy.

AU - Marquez, Victor E.

AU - Kelley, James A.

AU - Agbaria, Riad

AU - Ben-Kasus, Tisipi

AU - Cheng, Jonathan C.

AU - Yoo, Christine B.

AU - Jones, Peter A.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - 1-(Beta-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine) corresponds structurally to cytidine minus the exocyclic 4-amino group. The increased electrophilic character of its simple aglycon endows the molecule with unique biologic properties as a potent inhibitor of both cytidine deaminase and DNA cytosine methyltransferase. The latter activity makes zebularine a promising antitumor agent that is hydrolytically stable, preferentially targets cancer cells, and shows activity both in vitro and in experimental animals, even after oral administration.

AB - 1-(Beta-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine) corresponds structurally to cytidine minus the exocyclic 4-amino group. The increased electrophilic character of its simple aglycon endows the molecule with unique biologic properties as a potent inhibitor of both cytidine deaminase and DNA cytosine methyltransferase. The latter activity makes zebularine a promising antitumor agent that is hydrolytically stable, preferentially targets cancer cells, and shows activity both in vitro and in experimental animals, even after oral administration.

UR - https://www.scopus.com/pages/publications/33745312816

U2 - 10.1196/annals.1359.037

DO - 10.1196/annals.1359.037

M3 - Review article

C2 - 16394141

AN - SCOPUS:33745312816

SN - 0077-8923

VL - 1058

SP - 246

EP - 254

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -

Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy.

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this